Armstrong Juggles Reformulating Primatene Mist, Pushing To Sell Existing Inventory
This article was originally published in The Tan Sheet
Executive Summary
Armstrong Pharmaceuticals plans to submit in the fourth quarter an NDA to FDA for an OTC asthma inhaler reformulated without chlorofluorocarbon as a propellant. The House Energy and Power Subcommittee proposes allowing the firm to sell its remaining inventory of CFC-containing Primatene Mist.